CN108866102A - 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 - Google Patents
一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 Download PDFInfo
- Publication number
- CN108866102A CN108866102A CN201810635308.1A CN201810635308A CN108866102A CN 108866102 A CN108866102 A CN 108866102A CN 201810635308 A CN201810635308 A CN 201810635308A CN 108866102 A CN108866102 A CN 108866102A
- Authority
- CN
- China
- Prior art keywords
- mouse
- adgrv1
- gene
- y6236fsx1
- guide rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100434541 Mus musculus Adgrv1 gene Proteins 0.000 title claims abstract description 30
- 241001465754 Metazoa Species 0.000 title claims abstract description 18
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 42
- 108091033409 CRISPR Proteins 0.000 claims abstract description 39
- 108020004414 DNA Proteins 0.000 claims abstract description 28
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 25
- 238000011084 recovery Methods 0.000 claims abstract description 18
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 15
- 230000035772 mutation Effects 0.000 claims abstract description 14
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 11
- 235000013601 eggs Nutrition 0.000 claims abstract description 10
- 238000010172 mouse model Methods 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 2
- 206010011878 Deafness Diseases 0.000 description 7
- 208000014769 Usher Syndromes Diseases 0.000 description 7
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 6
- 101710096099 Adhesion G-protein coupled receptor V1 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010011882 Deafness congenital Diseases 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 201000008616 Usher syndrome type 1 Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是(1)设计并选择合适的靶向小鼠Adgrv1基因的Guide RNA及修复模板DNA;(2)体外合成Cas9 mRNA、Guide RNA和修复模板DNA;(3)将Guide RNA、Cas9 mRNA和修复模板DNA等摩尔比共同配制成注射样品对受精卵注射;(4)对获得的F0代小鼠进行鉴定;(5)阳性F0代小鼠传代及F1代小鼠的获得与鉴定。本方法可以成功获得与人类中Y6244fsX1致病突变对应的Adgrv1基因Y6236fsX1突变小鼠模型,为研究人类中Y6244fsX1致病突变的相关因素和诊断治疗提供了基础。
Description
技术领域
本发明属于利用基因修饰技术制作基因突变动物模型技术领域,具体涉及一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法。
背景技术
CRISPR/Cas(Clustered Regularly Interspaced Shot Palindromic repeats/CRISPR-associated)***是原核生物中一种抵抗外源基因侵入的获得性免疫***,在细菌和古生菌中CRISPR***整合侵入宿主的噬菌体或者质粒DNA片段到CRISPR位点,然后通过相应的CRISPR RNAs(cr RNAs)引导Cas核酸内切酶对外源DNA序列进行切割,从而抵抗病毒或者噬菌体的入侵。CRISPR/Cas***分为3种类型(TypeⅠ、TypeⅡ和TypeⅢ),其中TypeⅡ***因其简单、高效以及功能多样化等优点,自2013在哺乳动物细胞中成功实现基因编辑后,现已被广泛用于多种模式生物的基因组修饰技术应用中。Ⅱ型***可以通过crRNA的引导利用单个Cas9核酸酶对DNA靶位点进行精确充分地切割。CRISPR/Cas9***相关载体构建简单快速,便于操作,实验周期较短,且广泛适用于多个物种。在基因编辑的过程中,CRISPR/Cas9***需要一段特殊的引导RNA,即sgRNA(single guide RNA),sgRNA的序列选择限制性较小,只需要基因组序列中出现PAM(NGG)区即可。在sgRNA的引导下,Cas9蛋白可以对基因组实现定点切割,引起DNA双链断裂,继而引发细胞的自主修复,修复的过程可以是随机的片段缺失或***,也可以利用特定的模板修复,从而实现对基因组的永久性修饰。
Usher综合征(Usher syndrome,USH)是一种能够引起视觉和听觉双重感官障碍的遗传性疾病,在目前已知的超过50种的视力下降合并听力受损的综合征中,以Usher综合征最为常见,该病的全球发病率为1/6000~1/10000。USH为常染色体隐性遗传病,其特征表现为视网膜色素变性(retinitis pigmentosa,RP)和感音神经性耳聋(sensorineuralhearing loss,SNHL)。USH在临床上分为3种类型,都存在因视网膜色素变性而引起的进行性视力下降,区别在于听力和前庭功能的变现各不相同。其中USH1型最为严重,临床表现有先天性耳聋、严重的听力损失,并因听力障碍导致的语言发育迟缓;此类患者还经常伴有前庭功能障碍,患儿学会独立行走的时间较同龄儿童晚。USH2型患者听力损失较轻,为中到重度耳聋,但前庭功能正常。USH3型以渐进性听力损失为特点,伴随不同程度的前庭功能失调。此外,部分Usher综合征患者还可能伴有智力衰退,嗅觉丧失,癫痫等神经***病变。
ADGRV1是属于黏附受体亚家族(Adhesion receptor)的一种G蛋白偶联受体(GPCR),是听纤毛踝连接(Ankle-link)的重要组成成分,在听纤毛形成过程中起到重要的作用。ADGRV1是目前已知最大的GPCR蛋白,其mRNA经可变剪切产生不同的蛋白亚型。人ADGRV1 Y6244fsX1突变引起USH2综合征,临床表现为先天性耳聋和渐进性色素性视网膜炎,严重影响患者日常交流与工作学习等。目前对于ADGRV1突变致聋机制尚不明确,因此也缺乏有效的治疗手段。在小鼠中模拟人ADGRV1 Y6244fsX1突变,构建Adgrv1基因Y6236fsX1突变小鼠模型,对ADGRV1突变致聋机制进行深入探讨,以及利用这一模型进行药物筛选,具有重要的临床意义。但检索发现目前虽有Adgrv1基因敲除小鼠,没有仿真模拟人相关耳聋突变的小鼠模型,因此建立一种构建Adgrv1基因Y6236fsX1突变动物模型的方法意义重大。
发明内容
本发明的目的是提供一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法。
本发明所述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是:
(1)在小鼠Adgrv1基因89号外显子上6236位点Tyrosine附近设计合适的GuideRNA;其中引物Guide RNA target site1的核苷酸序列如SEQ ID NO.1所示,引物Guide RNAtarget site2的核苷酸序列如SEQ ID NO.2所示;设计合适的修复模板DNA以产生Y6236fsX1突变;其中修复模板DNA的核苷酸序列如SEQ ID NO.3所示;
(2)体外合成Guide RNA、Cas9 mRNA与修复模板DNA;
(3)将合成后的Guide RNA、Cas9 mRNA与修复模板DNA等摩尔比共同配制成100ul注射样品,并将样品注射到取自C57BL/6J母鼠受精卵的雄原核中,培养恢复后移植入假孕受体小鼠,等待获得的F0代小鼠;
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定;
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
上所述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法中:步骤(2)所述Guide RNA、Cas9 mRNA及修复模板DNA体外合成由生工生物工程(上海)股份有限公司完成。
上述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法中:步骤(4)所述PCR反应体系的引物为GPR98-test-F3和GPR98-test-R3;其中GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
本发明公开的基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法能够成功获得与人类中Y6244fsX1致病突变对应的Adgrv1基因Y6236fsX1突变小鼠模型。方法中涉及的设计并挑选合适的靶向小鼠Adgrv1基因的Guide RNA,难点在于寻找6236位Tyrosine附近合适的Guide RNA靶点以实现能够模拟人类Y6244fsX1突变的效果。本发明的构建方法为获得模拟人类Adgrv1基因Y6244fsX1致病突变的小鼠模型提供了便利,为研究人类中Y6244fsX1致病突变的相关因素和诊断治疗提供了基础。
附图说明
图1、Adgrv1基因Y6236fsX1突变小鼠构建策略图及基因鉴定引物设计。
图2、F0代阳性小鼠PCR产物测序图谱比对结果。
具体实施方式
如下实施例使用的Taq酶及PCR相关试剂购自TaKaRa公司。化学试剂主要购自Sigma和上海化学试剂公司。胶回收Kit,质粒抽提Kit购于Qiagen公司。修复模板DNA和RNA合成自生工生物工程(上海)股份有限公司。引物合成自英潍捷基(上海)贸易有限公司。
实施例1:基于CRISPR/Cas9技术构建Adgrv1基因Y6236fsX1突变动物模型的构建方法通过以下步骤实现:
(1)靶向小鼠Adgrv1基因的Guide RNA及修复模板DNA的选择和设计
设计Adgrv1基因Y6236fsX1突变小鼠构建策略,如图1所示。
根据构建策略,在Adgrv1基因相应的位置设计合适的Guide RNA,并订购相应的修复模板DNA,其中Guide RNA target site1的核苷酸序列如SEQ ID NO.1所示,Guide RNAtarget site2的核苷酸序列如SEQ ID NO.2所示,修复模板DNA的核苷酸序列如SEQ IDNO.3所示,具体序列如下:
(2)体外合成Guide RNA、Cas9 mRNA和修复模板DNA
Guide RNA、Cas9 mRNA和修复模板DNA由生工生物工程(上海)股份有限公司合成。
(3)受精卵显微注射制备F0代小鼠
1)单细胞受精卵的获得
小鼠超排:第一天,为C57BL/6J小鼠腹腔注射马绒毛膜***5IU/只,46-48小时后注射人绒毛膜***,注射完人绒毛膜***后将2只雌鼠与单放雄鼠1只合笼。第四天上午检栓,见栓的记为0.5天。
获取受精卵:将见栓0.5天后的小鼠脱颈处死,取出输卵管,在解剖镜下小心取出成团的卵子并用透明质酸酶消化,挑取形态饱满且胞质均匀的胚胎放置于M16培养液中培养。
2)显微注射受精卵
将挑选后的受精卵转移入M2条带中依次排列(30-50枚左右)。提前将Guide RNA、Cas9 mRNA及修复模板DNA等摩尔比共同配制成100ul注射样品,待注射管刺入受精卵后匀速将样品注入,见到胞质松散后迅速退针。注射结束后,将受精卵移入M16培养液中,并于37℃、5%二氧化碳培养箱中恢复0.5-1小时。将注射后的受精卵移植到E0.5天假孕小鼠体内。
移植后大约19-21天生出F0代小鼠。
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定
1)F0代小鼠基因组制备
F0代小鼠出生14天剪取鼠尾0.3cm,加400μl裂解液及40μl蛋白酶K(10mg/ml),56℃消化过夜。离心取上清,两倍体积无水乙醇沉淀,75%乙醇洗涤,稍晾干后溶解于100μl纯水中,50℃烘箱助溶1小时。
2)F0代小鼠基因型鉴定
以制取的F0代小鼠基因组为模板使用TaKaRa Lataq扩增鉴定片段,引物为GPR98-test-F3和GPR98-test-R3,如图1所示,可扩增出0.8kb条带。其中,GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
GPR98-test-F3:5′-ATCATAGCAATCTGCGTGTGACTCTGA-3′
GPR98-test-R3:5′-ACACTTTGGCAATGTTAGTTGCTTCTGA-3′
反应条件为94℃5min变性后,94℃40s,60℃30s,72℃1min,进行34个循环,72℃延伸2min,PCR体系参见TaKaRa说明书。
1%琼脂糖凝胶电泳后割胶回收0.8kb条带,分别连接pGEM-T载体(Promega),转化,每个平板挑取6个单克隆测序鉴定,引物为GPR98-test-F3。测序结果显示有19bp碱基缺失,如图2所示。
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
阳性F0代小鼠在8周龄左右性成熟后和野生型C57BL/6J回交进行配繁,得到F1代小鼠。同F0代相似,待小鼠出生14天后,剪尾进行PCR鉴定,得到5只F1代杂合子。
筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
序列表
<110> 山东大学
<120> 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法
<141> 2018-6-9
<160> 5
<170> PatentIn Version 3.5
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(20)
<223> Guide RNA target site1的核苷酸序列
<400> 1
ttcttctgga ggttatggcc 20
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(20)
<223> Guide RNA target site2的核苷酸序列
<400> 2
tcatcggcta tcagggaccc 20
<210> 3
<211> 98
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(98)
<223> 修复模板DNA的核苷酸序列
<400> 3
tttgaagaca agtccccaga atggtgcctc attcccttct tctggaggtt agccgatgaa 60
gagtcccagg agtttgatga cctgatattt gcattaaa 98
<210> 4
<211> 27
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(27)
<223> 引物GPR98-test-F3的核苷酸序列
<400> 4
atcatagcaa tctgcgtgtg actctga 27
<210> 5
<211> 28
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(28)
<223> 引物GPR98-test-R3的核苷酸序列
<400> 5
acactttggc aatgttagtt gcttctga 28
Claims (2)
1.一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是:
(1)在小鼠Adgrv1基因89号外显子上6236位点Tyrosine附近设计合适的Guide RNA;其中Guide RNA target site1的核苷酸序列如SEQ ID NO.1所示,Guide RNA target site2的核苷酸序列如SEQ ID NO.2所示;设计合适的修复模板DNA以产生Y6236fsX1突变;其中修复模板DNA的核苷酸序列如SEQ ID NO.3所示;
(2)体外合成Guide RNA、Cas9 mRNA和修复模板DNA;
(3)将Guide RNA、Cas9 mRNA与修复模板DNA等摩尔比共同配制成100ul注射样品,并将样品注射到取自C57BL/6J母鼠受精卵的雄原核中,培养恢复后移植入假孕受体小鼠,等待获得的F0代小鼠;
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定;
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
2.根据权利要求1所述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,其特征在于:步骤(4)所述PCR反应体系的引物为GPR98-test-F3和GPR98-test-R3;其中GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810635308.1A CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810635308.1A CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108866102A true CN108866102A (zh) | 2018-11-23 |
CN108866102B CN108866102B (zh) | 2021-11-16 |
Family
ID=64339662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810635308.1A Active CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108866102B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551759A (zh) * | 2018-12-28 | 2019-12-10 | 赛业(广州)生物科技有限公司 | 一种提高转基因细胞重组效率的组合物及方法 |
CN111778246A (zh) * | 2020-06-16 | 2020-10-16 | 首都医科大学附属北京同仁医院 | Sdk2基因突变小鼠模型构建方法及其应用 |
CN112005968A (zh) * | 2020-09-02 | 2020-12-01 | 南京农业大学 | 半乳糖基转移酶GalT基因点突变小鼠模型的构建方法及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106929533A (zh) * | 2017-03-10 | 2017-07-07 | 上海交通大学医学院附属新华医院 | Kars基因点突变小鼠模型的构建方法及其应用 |
CN107475300A (zh) * | 2017-09-18 | 2017-12-15 | 上海市同济医院 | Ifit3‑eKO1基因敲除小鼠动物模型的构建方法和应用 |
WO2018045727A1 (zh) * | 2016-09-06 | 2018-03-15 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
-
2018
- 2018-06-20 CN CN201810635308.1A patent/CN108866102B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018045727A1 (zh) * | 2016-09-06 | 2018-03-15 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
CN106929533A (zh) * | 2017-03-10 | 2017-07-07 | 上海交通大学医学院附属新华医院 | Kars基因点突变小鼠模型的构建方法及其应用 |
CN107475300A (zh) * | 2017-09-18 | 2017-12-15 | 上海市同济医院 | Ifit3‑eKO1基因敲除小鼠动物模型的构建方法和应用 |
Non-Patent Citations (1)
Title |
---|
QIAO-XIA HU等: "Constitutive Gαi Coupling Activity of Very Large G Protein-coupled Receptor 1 (VLGR1) and Its Regulation by PDZD7 Protein", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551759A (zh) * | 2018-12-28 | 2019-12-10 | 赛业(广州)生物科技有限公司 | 一种提高转基因细胞重组效率的组合物及方法 |
CN110551759B (zh) * | 2018-12-28 | 2021-10-15 | 广州赛业百沐生物科技有限公司 | 一种提高转基因细胞重组效率的组合物及方法 |
CN111778246A (zh) * | 2020-06-16 | 2020-10-16 | 首都医科大学附属北京同仁医院 | Sdk2基因突变小鼠模型构建方法及其应用 |
CN111778246B (zh) * | 2020-06-16 | 2022-04-19 | 首都医科大学附属北京同仁医院 | Sdk2基因突变小鼠模型构建方法及其应用 |
CN112005968A (zh) * | 2020-09-02 | 2020-12-01 | 南京农业大学 | 半乳糖基转移酶GalT基因点突变小鼠模型的构建方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN108866102B (zh) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
d'Amato | Nuclear cytology in relation to development | |
Liu et al. | Targeted disruption of tyrosinase causes melanin reduction in Carassius auratus cuvieri and its hybrid progeny | |
GB2578026A (en) | Method for constructing GLRX1 gene knock-out animal model based on CRISPR/CAS9 | |
CN108949824A (zh) | 基于HMEJ的方法介导Ipr1定点***获取转基因牛胎儿成纤维细胞的方法 | |
CN105505879B (zh) | 一种培养转基因动物胚胎细胞或转基因动物的方法及培养基 | |
CN108866102A (zh) | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 | |
CN106119284A (zh) | 一种用于构建免疫缺陷动物模型的产品及其应用 | |
CN106282231A (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN108893495A (zh) | 一种Pdzd7基因突变动物模型的构建方法 | |
CN109628464A (zh) | 一种增加大豆产量的方法 | |
CN109385431A (zh) | OsERF2基因调控水稻籽粒大小的应用 | |
CN106148406B (zh) | 猪ApoE基因敲除载体及其构建方法与应用 | |
CN108949832A (zh) | 一种用于敲除猪ghr基因的打靶载体及其应用 | |
CN115968834A (zh) | 一种rs1点突变小鼠模型的制备方法及其用途 | |
WO2021243881A1 (zh) | 用于猪MBP基因敲除的sgRNA组合物及用途 | |
CN109423499A (zh) | Mettl3敲除的***发生障碍动物模型及其构建方法 | |
KR101435635B1 (ko) | 넉인 벡터 및 이를 이용한 장기이식용 형질전환 동물의 제조방법 | |
CN106591364B (zh) | 一种获取转基因牛胎儿成纤维细胞的方法 | |
Navrátilová et al. | Biotechnological methods utilized in Cucumis research-A review | |
KR101068479B1 (ko) | 알파 1,3-갈락토실트랜스퍼라아제 유전자 타겟팅 벡터 및그의 용도 | |
CN104805100B (zh) | 水稻基因OsSμBP‑2在延缓植物叶片衰老中的应用 | |
KR20130106944A (ko) | 세포질 웅성 불임성을 가지는 nwb―cms 양채류 식물체 및 이의 용도 | |
CN106834270A (zh) | 一种离子束注入裂盖马鞍菌全基因组突变及定向进化的方法 | |
CN103923215B (zh) | 使ACC-α基因启动子PⅢ失活的物质及其应用 | |
CN101412999A (zh) | 一种基因打靶定点转基因方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |